$PVCT: Immunologic Potential, And Thus Value

Dec. 11, 2012 11:16 PM ETPVCT
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Contributor Since 2012

Note: I and others entered into a securities transaction with Provectus in March 2017. Please see my blog's Disclosures page and/or refer Provectus' Securities and Exchange Commission filings for further, future disclosures {Added 3/27/17}. ---- Entrepreneurship through corporate development and investment management. Board and advisory roles, portfolio management, private equity, trading, senior and start-up company management, and venture capital. Aerospace & defense, biotechnology, financial services, gaming, healthcare, nanotechnology, private wealth management. It's only work if somebody makes you do it (Calvin) Dominic Rodrigues

Taken From Connecting The Dots...Provectus Pharmaceuticals (December 11, 2012).

"The holy grail for cancer would be to trigger the body's own immune system to fight off the cancer so that you somehow stimulate the anti-bodies in a way that that happens." Fareed Zakaria, CNN GPS, from a December 9, 2012 interview with Dr. Ronald DePinho, President, M.D. Anderson Cancer Center

The progression of PV-10 & Provectus potential value

Click figure to enlarge it.

My expectation (above) most certainly is a very lofty one.

The conclusions of the forthcoming immunologic mechanism of action characterization work by Moffitt Cancer Center could be profound. Will Moffitt researchers make full-throated statements regarding PV-10's immunologic potential?

PV-10: A robust (strong), durable (long-lasting), portable (vaccine-like) immune-mediated response.

Disclosure: I am long OTC:PVCT.

Additional disclosure: I am a large shareholder of Provectus Pharmaceuticals. I have not sold any shares as of this Instablog submission.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.